Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2868 | SARS-CoV-2 antibody immunoassays Wiki | 0.71 |
drug3177 | Stellate Ganglion Block Wiki | 0.50 |
drug2448 | Placebo Wiki | 0.07 |
Name (Synonyms) | Correlation | |
---|---|---|
D045888 | Ganglion Cysts NIH | 0.41 |
D013577 | Syndrome NIH | 0.07 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
The primary objective is to evaluate the safety and efficacy of intravenous (IV) infusion of Ang (1-7) compared to placebo with respect to time to recovery, disease severity, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and mortality in patients with COVID 19.
Description: Time to recovery, defined as attaining a score of 6, 7, or 8 on the COVID-19 disease severity scale, an 8 point ordinal scale used in the NIH Adaptive COVID-19 Treatment Trial (ACTT; NCT04280705). = Death; = Hospitalized and on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); = Hospitalized and on non-invasive ventilation or high-flow oxygen devices; = Hospitalized and requiring supplemental oxygen; = Hospitalized and not requiring supplemental oxygen but requiring ongoing medical care (COVID-19-related or otherwise); = Hospitalized and not requiring supplemental oxygen and no longer requiring ongoing medical care; = Not hospitalized, limitation on activities and/or requiring home oxygen; = Not hospitalized, no limitation on activities
Measure: Time to recovery Time: Up to 29 daysDescription: COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Measure: COVID-19 disease severity scale score on Day 8 Time: Day 8Description: COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Measure: COVID-19 disease severity scale score on Day 15 Time: Day 15Description: COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Measure: COVID-19 disease severity scale score on Day 22 Time: Day 22Description: COVID-19 disease severity scale (range; 1-8, higher scores correspond to better health state).
Measure: COVID-19 disease severity scale score on Day 29 Time: Day 29The renin-angiotensin system (RAS) has a relevant role in COVID-19, as the virus will enter host's cells via the angiotensin-converting enzyme 2 (ACE2); RAS disequilibrium might also play a key role in the modulation of the inflammatory response that characterizes the lung involvement. Angiotensin-(1-7) is a peptide that could be altered in COVID-19 patient and its supplementation may potentially helpful in this setting.
Description: 28 - x, where x = number of days on which the patient is released from supplemental oxygen therapy after start
Measure: supplemental oxygen-free days (SOFDs) Time: 28 daysDescription: Hospital length of stay
Measure: Hospital length of stay Time: through study completion, on average 60 daysDescription: composite outcome of mortality and necessity of mechanical ventilation
Measure: ventilator free days Time: 28 daysDescription: number of days free from intensive care unit
Measure: ICU free days Time: through study completion, on average 40 daysDescription: Ang II and Ang-(1-7) circulating levels using mass spectrometry
Measure: RAS effectors levels Time: Baseline, 3 and 24 hours after randomization and 72 hours after randomizationDescription: CT scan evolutions compared to baseline including findings compatible with late pulmonary fibrosis.
Measure: CT scan findings Time: through study completion, on average 30 daysDescription: C-reactive protein levels daily measurements
Measure: Changes in inflammatory markers: C reactive protein Time: through study completion, on average 30 daysDescription: use of vasopressors during hospitalization
Measure: Changes in clinical state: vasopressors usage Time: through study completion, on average 30 daysDescription: Chest X-ray modifications until hospital discharge
Measure: Chest X ray findings Time: through study completion, on average 30 daysDescription: pro-inflammatory chemokine levels (IL-1/IL-6) at baseline day 3 and 7
Measure: Changes in inflammatory markers: chemokines Time: Baseline, 3 and 24 hours after randomization and 72 hours after randomizationDescription: Troponin plasmatic levels
Measure: Changes in inflammatory markers: troponin Time: Baseline, 3 and 24 hours after randomization and 72 hours after randomizationDescription: D-Dimer
Measure: Changes in thrombotic markers: D-Dimer Time: Baseline, 3 and 24 hours after randomization and 72 hours after randomizationDescription: Secondary infections recorded during hospitalization
Measure: Changes in clinical state: secondary infections Time: through study completion, on average 30 daysDescription: deep venous thrombosis recorded during hospitalization
Measure: Changes in clinical state: deep venous thrombosis Time: through study completion, on average 30 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports